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Abstract   
High mortality among hepatocellular carcinoma (HCC) patients reflects both late diagnosis and low 
curability, due to pharmacoresistance. Taxol (TAX) is toxic for many  human HCC-derived cell lines, yet its 
clinical efficacy on HCCs is poor. Combining TAX with other drugs appears a promising possibility to 
overcome such refractoriness. We analysed whether combining tumor necrosis factor (TNF) with TAX 
would improve their toxicity. HCC-derived cell lines were treated with TAX or TNF, alone or combined. 
Apoptosis  was assessed by morphology and flow-cytometry. Several pro- and anti-apoptotic molecules were 
evaluated by western blotting and/or enzymatic assay.  After a 24 hour  treatment, TNF was ineffective and 
TAX modestly cytotoxic,  whereas HCC cells were conditionally sensitized to TNF by TAX.  Indeed some 
relevant parameters were shifted to a prodeath setting: TNF-receptor 1 was increased, SOCS3, c-FLIP and 
pSTAT3 were markedly downregulated. These observations provide a significant clue to critically improve 
the drug susceptibility of HCC cells by combining two agents, TAX and TNF. The sequential application of 
TAX at a low dosage followed by TNF for only a short time triggered a strong apoptotic response. Of 
interest, prior TAX administration could also sensitize to TNF-induced apoptosis in the Yoshida AH-130 
hepatoma transplanted in mice. Therefore, scrutinizing the possibility to develop similar combination drug 
regimens in suitable preclinical models seems highly advisable.  
 
Running title: Taxol strongly sensitizes human HCC cells to TNF 
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tanscription 3; TAX, taxol (paclitaxel); TNF, tumour necrosis factor-α; TNF-R1, TNF-receptor 1; TRAIL, 
tumour necrosis factor-related apoptosis-inducing ligand. 
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Introduction 
Taxol (TAX, Paclitaxel), originally isolated from the yew tree Taxus brevifolia, is prototypic of a family 
of powerful anticancer agents collectively known as taxanes. These spindle poisons share a unique 
mechanism of action: they bind to polymerized β-tubulin, profoundly alter its dissociation constant at both 
microtubule ends and promote β-tubulin polymerization. The results are suppression of treadmilling and 
dynamic instability causing stabilization of microtubules in a straight conformation that prevents cell 
division. 
1 
Proliferating cells thereby undergo an arrest at the G2/M phase of the mitotic cycle 
2
, more 
precisely in metaphase, followed by death, as reported for a variety of human neoplastic lines. 
3-6
 Commonly 
used in the treatment of solid tumours such as breast, head and neck, ovarian and non-small-cell lung 
carcinomas even as a front-line drug 
7
, often their clinical efficacy is heavily hampered by chemoresistance, 
either primary (constitutive) or secondary (acquired as a consequence of treatment), due to a multiplicity of 
mechanisms. 
8, 9
 
HCC ranks as the sixth most frequent solid malignancy and the fifth leading cause of cancer-associated 
death worldwide. 
10
 Since generally diagnosed too late for surgical resection or transarterial 
chemoembolization to be curative, search for effective chemotherapies is a major task in this field. TAX, 
which easily crosses the plasma membrane, exerts a marked toxicity on HCC-derived cell lines, as shown by 
numerous studies 
3, 6, 8, 11
, and significantly inhibits both tumour growth and angiogenesis in human HCCs 
with high metastatic potential xenografted into nude mice. 
12
 TAX compromises viability of  human HCC 
cell lines even at quite low concentrations,  just greater than 10 nM 
3
, with  IC50 values of 80 nM to 1 µM, as 
respectively observed in death prone and death reluctant HCC cells. 
13
 Yet most HCCs are refractory to 
taxanes and TAX efficacy proved negligible in phase I 
14
 and phase II 
15
 trials. 
The therapeutic potential of this mitotic poison family was explored by studies aimed at unveiling the 
basis for the ‘constitutive’ drug resistance of HCCs. Function (activity/expression) of  prosurvival factors 
was found enhanced and, by contrast, that of prodeath factors decreased in HCCs, not differently from other 
cancers. In particular, the imbalance between cell death and survival in HCC mainly reflects multiple 
modulations of antiapoptotic molecules including c-FLIP, Bcl-2/Bcl-xL 
8
 and/or signaling pathways such as 
RAS/ERK, PI3K/Akt, JAK/STAT, as well as defective proapoptotic mediation by p53, TGF-β, Fas, TRAIL. 
16
 Recently, an important role in the response to TAX has been advocated for the JNK activation state by 
Chae et al. 
13
, who distinguished death prone and death reluctant HCC cell lines: on TAX administration, 
Bcl-2 was highly phosphorylated in the former, much less in the latter. Both degree of Bcl-2 phosphorylation 
and death of prone cells were strongly attenuated by the JNK inhibitor SP600125, whereas death reluctant 
cells had high inbuilt levels of phospho-JNK, JNK being much less or not any further phosphorylated upon 
TAX treatment. Interestingly, JNK activation was also suggested to play a role, though still debated, in HCC 
cell apoptosis by death receptor ligands such as TRAIL and TNF. 
17
 
        A different line of investigations addressed the design of combined treatments, testing a number of 
simultaneous or sequential associations of TAX with other antineoplastic agents. For example, TAX exhibits 
a synergistic lethal action on HCC cell lines when used in combination with oncolytic adenoviruses 
18
, whereas 
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TAX and doxorubicin exert an additive toxicity on HepG2 cells and  cause a regression of the H22 tumour in 
mice significantly higher than that afforded by either drug individually. 
19
  Recently,  the synergistic effects of 
IAP inhibitor LCL161 and TAX on HCC cell lines has been reported.20  Along this line, a number of studies 
also evaluated the efficacy of combining TAX and alike drugs with death receptor ligands, particularly 
TRAIL and TNF (see Discussion).  In this regard, the transcription factor STAT3 was reported to play a 
critical role in TAX sensitization to TRAIL or TNF, ascribed to decreased activity owing to its reduced 
degree of Tyr-phosphorylation.   
The concept that sequential application of anticancer drugs can enhance neoplastic cell death by 
rewiring apoptotic signaling networks was worked out by Lee et al. 
21
 based on the observation that breast 
cancer cells were dramatically sensitized to genotoxic drugs by time-staggered EGFR inhibition, though not 
by simultaneous cotreatment. A distinct yet equally effective mode of rewiring that sensitizes cancer cells to 
apoptosis is the object of the present report, which is part of a line of investigations developed in our 
laboratory to dissect the mechanisms of the deadly action on HCC cells by TNF, alone or combined with 
other drugs. 
17, 22-24
 We presently sought whether associating TAX with TNF - which individually display 
only moderate or no toxicity at all, respectively - would significantly enhance their deadly action on two 
different human HCC-derived cell lines, viz., Huh7 and HepG2. Both lines, but Huh7 in particular, are 
dramatically sensitized to TNF-induced death by simultaneous or prior exposure to TAX. Adopting various 
schedules of concurrent or sequential treatment disclosed a very marked toxicity when TAX and TNF were 
applied simultaneously or even in sequence, though not in the reverse order, at appropriate time intervals, 
sufficient for TAX to bring most cells to a G2/M cycle phase arrest and to reprogram relevant apoptotic 
pathways. These results will hopefully provide a frame of reference for future developments at a preclinical 
and possibly clinical level of checking. 
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Results 
Effects of TAX on HCC cell lines 
In Huh7 and HepG2 cells treated with 0.1 to 5 µM TAX for up to 24 hours the percentage of apoptotic 
(hypodiploid or sub-G1 or hypochromic, with <2n DNA fluorescence) cells significantly increased in a time- 
and dose-dependent manner  (Fig.1A,B). At the lowest TAX concentration (0.1 µM), the growth curve was 
equally flat for both lines (Fig.C,D), which denotes a complete growth arrest, with most cells exhibiting a 
rounded-up morphology and only few cells plasma membrane blebbing (Fig.1E,F). After 24 hours, an almost 
complete G2/M arrest (Fig.2A) associated with a roundish morphology (Fig.1E,F) were induced by TAX in 
both lines. Huh7 cells appeared more susceptible to TAX than HepG2 (Fig.1 and Fig.2). The fraction of sub-
G1 (apoptotic) cells in TAX-treated Huh7 cultures, while not differing from controls at 6 hours (about 8%), 
significantly increased up to 23% at 24 hours (Fig.2B). In TAX-treated HepG2 cultures the percentage of 
hypodiploid cells at 6 hours (about 5%) did not differ from controls, but at 24 hours approximated 15% 
(Fig.2B).  
 
TAX sensitizes HCC cell lines to TNF cytotoxicity 
In agreement with previous reports on HCC cell lines 
22, 25-27
, Huh7 and HepG2 cells both revealed 
totally resistant to TNF alone, the percentage of hypodiploid cells not differing between control and 
cytokine-treated cultures (Fig.3A) 
To evaluate a possible interaction between TAX and TNF, HCC cells were first exposed simultaneously 
to both drugs for 24 hours. Compared to TAX alone, the combined treatment resulted in a significant 
increase of the apoptotic population, from about 25% to 65% for Huh7 and from about 15% to 43% for 
HepG2 cells (Fig.3A). In an attempt to discriminate the respective role of the two drugs when used in 
combination, cells incubated in the presence of TAX for 12 to 30 hours were exposed also to TNF in the last 
6 hours only and, reciprocally, cells treated with TNF for 30 hours were exposed to TAX in the last 6 hours. 
Other cultures were treated for 30 hours with TAX alone or combined with TNF. As depicted in Fig. 3B, 
treatment with TAX followed by TNF significantly and time-dependently enhanced the fraction of 
hypodiploid cells, although the latter remained below that caused by 30 hour TAX+TNF treatment. By 
contrast, the percentage of apoptotic cells did not differ from controls when TAX was added for the last 6 of 
a 30 hour exposure to TNF. 
Noteworthily, other spindle poisons such as nocodazole (NOC) or colchicine (COL), which affect 
microtubules through different mechanisms, had basically similar effects to those obtained with TAX on the 
viability of HCC cells. In fact, the percentage of apoptosing cells was comparable among cultures exposed to 
TAX, NOC or COL (Fig.3A), suggesting that sensitization of HCC cells to TNF, rather than being TAX-
specific, may reflect a common effect on cells. 
 
Caspase activation  
To investigate whether caspases were involved in HCC cell death, the TAX+TNF treatment was carried 
out in the presence of the polycaspase inhibitor zVADfmk. As Fig.3C shows, 20 µM zVADfmk markedly 
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reduced apoptosis in both cell lines, approximately down to the level observed in cells treated with TAX 
alone. Interestingly, while TAX-induced death proved virtually caspase–independent, in that only minimally 
suppressed by zVADfmk, apoptosis by TAX+TNF was largely dependent on caspases, particularly in Huh7 
cells.  
The occurrence of caspase activation was confirmed by enzymatic assays. On TAX treatment, caspase 8 
activity was increased in Huh7 cells at 24 hours, while activation was already evident after 2 hours on 
TAX+TNF (Fig.4A). In HepG2 cells caspase 8 activity gradually increased from 2 to 24 hours both on TAX 
and, to a higher degree, on TAX+TNF (Fig.4B). In both cell lines, activation of caspases 3 and 9 was also 
observed, particularly in cultures exposed to TAX+TNF (Fig.4C-F); of interest, the increase of caspase 9 
activity was detectable only after a 24 hour treatment, suggesting that its role in TAX+TNF-induced 
apoptosis is marginal. Moreover, the caspase 8 inhibitor zIETDfmk suppressed both caspase 8 and 3 
activation, which is a plausible indication of a causal link between the two processes, whereas AcDEVDcmk 
only reduced caspase 3 (Fig.5A,B). These data are all consistent with an involvement of the extrinsic 
pathway in TAX+TNF-induced apoptosis.  
 
Effects of TAX on TNF-R1, SOCS3, c-FLIP and pSTAT3 levels 
TNF cytotoxicity is a highly regulated process that integrates a multiplicity of positive or negative 
pathways and factors. A few among the latter were examined in the present work: total and cell surface 
expression of TNF-R1 and total levels of SOCS3 and c-FLIP, the first two being involved in TNF cytotoxic 
signal transduction, the third one in the activation of the caspase cascade that typifies the extrinsic apopotic 
mechanism. 
TNF-R1 levels were reduced in total extracts of both Huh7 and HepG2 cells exposed to TAX, alone or 
combined with TNF (Fig.6A-D). Cell-surface expression of the receptor was then evaluated on non-
permeabilized cells by two different procedures. By immunofluorescence microscopy, TNF-R1 cell surface 
levels appeared higher in 24 hours TAX-treated cultures than in controls (Fig.6E,F). Although, to some 
extent, this finding could reflect the roundish morphology acquired by cells on TAX treatment, flow-
cytometric assays indicated as well that TNF-R1 was significantly more expressed (Fig.6G,H) at the surface 
of Huh7 cells treated with TAX and, even more, with TAX+TNF. Similar results were obtained in HepG2 
cells, although TNF-R1 membrane expression did not further increase in TAX+TNF vs TAX-exposed 
cultures.  
An important role in cytokine cytotoxicity is played by molecules known as SOCS, among which 
SOCS3 is involved in TNF action.
28, 29
 SOCS3 expression was markedly down-regulated in both Huh7 and 
HepG2 cells exposed to TAX and even more, though in Huh7 cells only, to TAX and TNF cotreatment 
(Fig.7A,B). To validate the relevance of SOCS3 down-regulation operated by TAX to TNF cytotoxicity, 
cells were knocked down for SOCS3 expression by the use of specific siRNA (siSOCS3). This manipulation 
resulted in an appreciable decrease of SOCS3 protein (Fig.7C) and, consistently, in an increased fraction of 
apoptotic cells, already evident in the absence of any further treatment, but markedly enhanced on exposure 
of siSOCS3 cells to TNF (Fig.7D).  
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The level of c-FLIP, the physiological caspase 8 inhibitor, is known to undergo important up- or down-
regulations that significantly impact on the apoptotic susceptibility of cells. As Fig.8A-D shows, this level 
was significantly decreased in both Huh7 and, to a lesser extent, HepG2 cells by TAX or TAX+TNF 
treatment. Again, this change is consistent with the sensitizing action of TAX towards TNF in HCC cells. 
Finally, Walker et al. 
30, 31
 recently reported an important inhibiting effect of TAX and other 
microtubular drugs on STAT3. This transcription factor modulates the expression of genes among which c-
FLIP and SOCS3 as a function of the degree of its Tyr-phosphorylation. This observation prompted us to 
evaluate the STAT3 phosphorylation status in the present experimental models. The pSTAT3 level markedly 
declined in both Huh7 and HepG2 cells exposed to TAX, either alone or combined with TNF, roughly 
paralleling SOCS3 level changes (Fig.7A,B); however, SOCS3 was almost undetectable in Huh7 cells 
treated with TAX+TNF. 
In conclusion, whether combined or not with TNF, TAX determines changes in all the parameters 
herewith investigated in such a way that they should expectedly converge in enhancing the susceptibility of 
HCC cells to TNF. Importantly, these changes were definitely less pronounced in HepG2 than in Huh7 cells, 
in agreement with their dissimilar vulnerability to TAX+TNF. Whether these observations may relate to the 
reports 
32, 33
 of an enhanced proliferative capacity of hepatocytes in mice carrying a specific hepatocytic 
deletion of SOCS3 or in HCC cell lines silenced for SOCS3 expression 
34
 is presently unclear.  
 
Potentiation of TAX-induced cytotoxicity by TNF in a transplantable hepatoma 
Preliminary experiments on a transplantable ascites hepatoma were run in order to test if the TAX-
induced potentiation of TNF cytotoxicity observed in human HCC cell lines also occurs in the AH-130 
Yoshida ascites hepatoma transplanted in mice. As Fig.9 shows, TNF or TAX alone increased the number of  
apoptotic (sub-G1) cells, slightly the former and markedly the latter. Simultaneous administration of the two 
drugs resulted in a further increase in the fraction of sub-G1 cells (Fig.9A). Qualitatively, the pattern is 
consistent with that reported for both Huh7 and HepG2 cells. Moreover, SOCS3 levels underwent a 
significant reduction in TAX-treated tumours that was further enhanced when TAX was coupled with TNF 
(Fig.9B,C), similarly to what observed on HCC cells. 
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Discussion 
 
TAX is poorly effective in the therapy of human HCCs 
14, 15
, despite its capability to induce apoptosis in 
vitro in a variety of human HCC-derived cell lines. This failure, either manifest ab initio or emerging in the 
course of treatment, spurred many efforts to decipher the mechanisms underlying TAX chemoresistance. 
Alternatively, a variety of procedures were devised to overcome such refractoriness, a preferred strategy 
being to combine TAX with other antineoplastic agents or death receptor ligands such as TRAIL and TNF. 
Falling into the latter category, the present work was focused on the cooperation between TAX and TNF in 
mounting a strong toxic effect on human HCC cells and its results led to formulate the rationale for a novel 
antiblastic approach. In short, after a 24 hour treatment TAX caused cell cycle arrest in the M phase 
associated with a moderate degree of apoptosis in two human HCC cell lines, Huh7 and HepG2, in 
agreement with previous observations 
3, 6, 11
.
 
By contrast, no toxic action at all on these cells was displayed by 
TNF per se. However, simultaneously exposing cells to TAX and TNF for up to 24/30 hours strongly 
enhanced apoptosis with respect to TAX alone, with Huh7 exhibiting a higher susceptibility than HepG2 
cells. Noteworthily, similar results could be largely reproduced substituting TAX with spindle poisons such 
as COL and NOC, which compromise microtubules through a different mechanism. The data thus seem to 
suggest that, rather than a sensitization to TAX by TNF, the reciprocal effect came into play. To clarify the 
issue, Huh7 and HepG2 cells were sequentially exposed to TAX for up to 24/30 hours followed by TNF in 
the last 6 hours of incubation. This schedule markedly boosted apoptosis, whereas exposure to the same 
drugs in the reverse order (TNF followed by TAX) resulted in no significant change in the frequency of 
apoptotic cells with respect to TNF alone.  
       Some kinds of cooperation between death ligands and spindle drugs in inducing apoptosis in various 
tumours or neoplastic cells were previously reported. Just few examples adequately illustrate this point. 
Daily TNF administration over a week associated with a single quite high dose of TAX on the second day 
resulted in an additive or superadditive effect in mice developing tumours after inoculation of cancer cells 
derived from HCC or other carcinoma lines. This effect was ascribed to increased TNF-dependent 
antitumour efficacy of TAX 
35
; however, the experimental design was such as to preclude an univocal 
interpretation about the relative contribution of each drug to anti-tumoural cytotoxicity. Apoptosis of human 
prostate cancer cells was conspicuously enhanced by TRAIL supplemented to cultures previously exposed to 
TAX 
36
, or also to chemotherapeutic drugs such as etoposide, doxorubicin, vincristine and camptothecin. 
37
 
Compared to either drug alone, combined treatment with TAX and TRAIL increased apoptotic death in 
human non-small-cell lung 
38
, prostate or bladder cancer cells. 
37
 Similarly, apoptosis was enhanced in 
human glioblastoma multiforme and colon cancer cell lines exposed to nocodazole and TRAIL. 
39 
How a former exposure to TAX may condition cells towards TNF toxicity was herewith explored in 
preliminary experiments. The relevant parameters examined were found all altered by TAX in HCC cells in a 
way expected to favor TNF toxicity: (i) the amount of TNFR1 exposed on the cell surface definitely 
increased, in spite of its decreased total levels; (ii) the content of the suppressor SOCS3 markedly decreased; 
(iii) c-FLIP, the physiological inhibitor of caspase 8 activation, significantly decreased as well. Notably, 
10 
 
these changes were quite marked in Huh7 and less so in HepG2 cells, roughly paralleling their different 
susceptibility to TAX+TNF.  
           Recently, a new light was shed on the toxicity of TAX, and other microtubule inhibiting drugs as well, 
by the observation that these agents exert an important inhibitory action on STAT3 by decreasing its Tyr-
phosphorylation. 
30, 31
 STAT3 is a transcription factor involved in the control of cell proliferation, 
differentiation, survival, and death and c-FLIP and SOCS3 are two of the genes whose expression is 
modulated by STAT3. STAT3 activation is known to be inducible by cytokines, but also constitutive in 
many of the microtubule drug-responsive tumours. In both instances, it is rapidly inhibited by TAX, within 6 
h of treatment, through induction of a putative negative feedback regulator. 
31
 The present data demonstrate 
that pSTAT3 levels markedly decrease in Huh7 cells treated with TAX or, even more, with TAX+TNF, 
roughly paralleling their effect on SOCS3 expression, whilst changes were less pronounced in HepG2 cells. 
The mechanism underlying the TAX effect requires further analysis, but the present observations at least 
support the contention that TAX somehow causes cells to reprogram TNF-triggered signaling pathways, 
thereby strongly promoting the susceptibility to TNF of cells otherwise not responsive at all. However, other 
possible mechanisms should not be ruled out as yet. Interesting, in this regard, is the recent report 
40
 that c-
FLIP downregulation by TAX depends on the action of the negative regulator MiR-512-3p, rather than on 
decreased mRNA levels. 
The death process set in motion by TAX+TNF is caspase-mediated and zVADfmk-suppressed, largely 
at least, an observation in full agreement with the above changes of TNF signaling mediators elicited by 
TAX in HCC cells. Generally speaking, these findings also fit very well evidence in the literature suggesting 
that taxanes such as TAX and other antimicrotubular drugs promote cytokine-induced apoptosis, which 
generally occurs in association with upregulation of the cognate receptors and develops along the extrinsic 
pathway. 
36, 37, 41
 Interestingly, apoptosis by TRAIL in TAX-treated PC-3 cells was found more marked than 
in cells exposed to the same drugs in the reverse order 
36
, which is reminiscent of the present observations. 
According to several reports 
42
, various cell lines treated with anticancer agents such as cisplatin or curcumin 
also increase cell surface expression and clustering of death receptors, thereby being sensitized to the 
cytotoxic action of death ligands. How precisely the above drugs reset the cell susceptibility to death ligands 
largely remains conjectural, however. 
The present work shows that sequential application of two anticancer drugs such as TAX and TNF can 
enhance neoplastic cell death by some sort of rewiring of the apoptotic signaling networks. TAX strongly 
sensitizes to TNF cytotoxicity two human HCC cell lines, Huh7 and HepG2, otherwise refractory to the 
cytokine by itself. Exposing either cell type to TAX and TNF combined for 24/30 hours markedly enhances 
apoptosis, well above the low levels attained by TAX alone. A similar albeit lesser effect is achieved by 
applying the two drugs sequentially, i.e., TAX for 24/30 hours and TNF for only the last 6 hours of the total 
incubation time. Decreased total levels of SOCS3 or c-FLIP, to be likely ascribed to reduced Tyr-
phosphorylation of STAT3, and increased TNF-R1 expression on the plasma membrane presumably 
concurred in TAX-engendered cell sensitization to TNF. Irrespective of the precise mechanism involved, the 
present findings show that a strong cytotoxic action can be achieved in cell cultures by applying the two 
11 
 
drugs in an appropriate sequence. A major oppotunity offered by this schedule is the possibility to employ 
TAX at a low concentration (0.1 µM was used in the present work) and, on the other hand, to apply TNF for 
only a short time (potentially profitable in view of the short half-life of serum TNF). Therefore, the present 
findings appear to outline a novel promising strategy to overcome drug resistance in cancer therapy: a 
sequential drug combination that might maximize curative effects while minimizing adverse reactions. 
12 
 
Materials and Methods 
 
Cell lines 
Huh7 cells originally derive from a patient affected by a well differentiated HCC, in the absence of 
HBV infection 
43
, replicate continuously and are characterized by an epithelial-like morphology (Japanese 
Collection of Research Bioresources). HepG2 cells (ATCC), retaining features of differentiated hepatocytes 
and an epithelial morphology, were isolated from a hepatoblastoma. Both lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma) supplemented with 10% foetal bovine serum, 100 U/ml 
penicillin, 100 g/ml streptomycin and 2 mM L-glutamine. Cells were grown at 37°C in a humidified 
atmosphere containing 5% CO2. At each experimental time pointculture media were collected and 
centrifuged (500 x g, 10 min at 4°C). Monolayers were washed with PBS-EDTA, trypsinized and centrifuged 
as above. Cells obtained from medium and monolayer were resuspended in PBS, pooled and counted in the 
presence of trypan blue.  
 
Drugs and treatments 
Cells were exposed to 0.1 µM TAX (Sigma), 0.2 µg/ml nocodazole (NOC), or 10 µM colchicine (COL) 
in the presence or in the absence of 15 ng/ml TNF (Peprotech) 48 hours after plating. Cultures were 
supplemented with the polycaspase inhibitor zVADfmk (Alexis Laboratories) at 20 μM final concentration 
or with 20 µM caspase 3 or 8 selective and irreversible inhibitors AcDEVDcmk or zIETDfmk, respectively 
(Calbiochem) one hour before treatment with antimitotic drugs and/or TNF. 
Caspase inhibitors, TAX and NOC were dissolved in DMSO (Sigma), TNF in DMEM and COL in 
ethanol. Control experiments ruled out any effect of DMSO or ethanol by themselves (data not shown).  
 
DAPI staining 
To detect changes in nuclear morphology characteristic of apoptosis, cells were washed with PBS, fixed 
with 95% ethanol for 5 min at room temperature (RT), dark-incubated for 20 min with 1 μg/ml DAPI (4,6-
diamidino-2-phenylindole dihydrochloride), then washed two times with PBS to remove fluorochrome 
excess. Cells were observed in a fluorescence microscope (Leitz Dialux 20) and photographed (Coolpix 
4500, Nikon). 
  
Membrane expression of TNF-R1  
Immunofluorescence microscopy. Cells were washed with PBS, fixed in 3.7% paraformaldehyde 
(Sigma-Aldrich, Milan, Italy) for 30 min, incubated at RT in 1% bovine serum albumin in PBS and 
overnight at 4°C with anti-TNF-R1 rabbit  polyclonal antibody (1:50; Santa Cruz Biotechnology). Cells were 
then washed twice with PBS and incubated for 1 hour at RT with FITC-conjugated goat anti-rabbit 
secondary antibody (1:150; Sigma). After permeabilization with 0.05% (v/v) Triton X-100 in PBS, nuclei 
were stained with DAPI. Samples were observed by fluorescence microscopy and photographed.  
13 
 
Flow-cytometric analysis. 25x10
4 
 cells were exposed to TAX, TNF or TAX+TNF for 24 hours, washed 
with PBS-EDTA, trypsinized and rinsed thrice with washing buffer (WSB: PBS containing 2% foetal calf 
serum and 0.1% NaN3). After centrifugation at 500 x g for 1 min at RT, cells were incubated for 5 min in 10 
µl of PBS containing 1% BSA and 0.1% NaN3, then in 40 µl of FITC-labeled anti-TNF-R1 monoclonal 
antibody (20 µg/ml; MBL)  for 30 min at RT, washed with WSB, pelleted by centrifugation for 1 min at 500 
x g and resuspended in 500 µl of WSB. Labeled cells were analysed in a FACScan flow cytometer using the 
CellQuest software (Becton & Dickinson).   
 
Cell cycle and DNA distribution analysis 
Cell cycle progression and DNA distribution were analysed by flow cytometry using propidium iodide 
staining. Cell cultures were washed with PBS-EDTA, trypsinized and centrifuged (500 x g, 10 min at 4°C). 
Apoptotic bodies were obtained by centrifugation of the supernatant at 1500 x g for 10 min. After washing, 
cells and apoptotic bodies were separately fixed in ice-cold 70% ethanol for at least 30 min at RT. 
Subsequently they were centrifuged as indicated above, put together in PBS containing DNase-free RNase A 
(0.4 mg/ml) and incubated for 30 min. Then, cells were incubated 10 min with propidium iodide (0.18 
mg/ml) and analysed by flow cytometry using the CellQuest software (Becton & Dickinson). The apoptotic 
population was estimated by evaluating the percentage of cells characterized by a <2n DNA fluorescence 
(hypodiploid or subG1 cells). 
44
 
 
Downregulation of SOCS3 by RNA interference 
 One day prior to transfection, cells were seeded (10
4
/cm
2
) without antibiotics in 6 cm Petri dishes in a 
total volume of 3 ml DMEM supplemented with 10% foetal bovine serum. Cells were then transfected using 
10 µl Lipofectamine 2000 reagent (Invitrogen), 300 µl OptiMEM (Invitrogen) and 100 pmol siRNA (control 
and human siSOCS3 specific; MWG-Biotech AG) for 24 and 48 hours. The sequence for SOCS3-targeted 
siRNA (siSOCS3) was 5’-CCUGGUGGGACGAUAGCAACC-3’. 45 Transfected cells were then treated 
with TNF 48 hours after transfection. Nontargeting siRNA was used as control (siC).  
 
Immunoblot analysis 
Cells were sonicated in lysis buffer (PBS containing 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% 
SDS, 0.1 mM PMSF, 2 g/ml aprotinin and 100 mM sodium orthovanadate) to obtain total extracts. Protein 
concentration was assayed according to a modified Bradford technique using an assay kit (Bio-Rad). Equal 
amounts of protein (30 µg) were heat-denaturated in sample-loading buffer (50 mM TRIS-HCl, pH 6.8, 100 
mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol), resolved by SDS-PAGE (12% polyacrilamide, 
0.1% SDS) and transferred to nitrocellulose membranes (Bio-Rad). Filters were then blocked with Tris-
buffered saline (TBS) containing 0.05% (v/v) Tween and 5% non-fat dry milk, then incubated overnight with 
a mouse polyclonal anti-SOCS3 antibody (1:100; Santa Cruz Biotechnology) or a rabbit polyclonal anti-c-
FLIP antibody (1:1000; Sigma), anti-STAT3 and anti-pSTAT3 antibodies (1:1000; Cell Signaling) and anti-
TNF-R1 (1:200; Santa Cruz Biotechnology). Goat anti-rabbit and anti-mouse peroxidase-conjugated IgG 
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(Bio-Rad) were used as secondary antibodies. Filters were then stripped by incubation in 62.5 mM Tris-HCl, 
pH 6.7, containing 100 mM 2-mercaptoethanol and 2% SDS for 30 min at 50°C, and reprobed with a mouse 
polyclonal antibody directed against β-actin (1:2000; Sigma) to normalize sample loading. The membrane-
bound immune complexes were detected by enhanced chemiluminescence (Santa Cruz Biotechnology) on a 
photon-sensitive film (Hyperfilm ECL; Amersham Biosciences). Band quantification was performed by 
densitometric analysis using a specific software (TotalLab, NonLinear Dynamics). 
 
Caspase enzymatic activity 
Caspase activities were assayed on cell lysates by evaluating the cleavage of fluorogenic substrates. 
Cells resuspended in lysis buffer (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1 mM Na-EDTA, 1 mM DTT, 
1 mM PMSF and 10 g/ml leupeptin), were maintained on ice for 15 min, sonicated and then centrifuged at 
13,000 rpm for 15 min at 4°C (Biofuge 17 RS, Heraeus Sepatech). The supernatant was collected and protein 
concentration determined.  
Aliquots of 30 µg protein were then incubated in reaction buffer (25 mM HEPES, pH 7.5, containing 
0.1% CHAPS, 10% sucrose, 10 mM dithiothreitol, 0.1 mg/ml ovalbumin) for 60 min at 37°C in the presence 
of 20 µM fluorogenic substrates for caspase 3, 8 and 9 (respectively Ac-DEVD-AMC, Ac-IETD-AMC and 
Ac-LEHD-AMC), all purchased from Biomol (Philadelphia). Reaction was blocked with 0.01% ice-cold 
trichloroacetic acid and fluorescence read at 380 nm excitation and 460 nm emission in a spectrofluorometer 
(Perkin-Elmer). Specific activities, expressed as nkatal/mg protein, were calculated by using free AMC as 
working standard. 
 
Experiments on tumour-bearing mice 
The study was performed on male Balb/c mice weighing about 20 g (Charles River), cared for in 
compliance with the Italian Ministry of Health Guidelines (n° 86609 EEC, permit number 106/2007-B) and 
the Policy on Humane Care and Use of Laboratory Animals (NIH 1996). The experimental protocol was 
approved by the Bioethical Committee of the University of Torino. Animals were maintained on a regular 
dark-light cycle (light from 08:00 to 20:00), with free access to food and water during the whole 
experimental period. Tumour-bearing (TB) mice received an intraperitoneal (i.p.) inoculum of Yoshida AH-
130 ascites hepatoma cells (5105 cells/mouse; tumour provided years ago by Prof. U. Del Monte, University 
of Milano, Italy, and maintained in our lab by weekly i.p. transplantation). Despite this tumour is typically 
grown in rats, it also engrafts in mice. The animals were divided into four groups (n = 4/group), namely, 
untreated TB, TNF-treated TB, TAX-treated TB and TAX+TNF-treated TB. Six days after tumour 
transplantation both TAX and TAX+TNF-treated mice received an i.p. injection of TAX (4 mg/kg). 
35
 After 
24 hours TNF and TAX+TNF-treated animals were administered TNF (10 μg/mouse, i.p.). 35 All the animals 
were sacrificed 6 hours later under isofluorane anesthesia. Tumour cells were collected from the peritoneal 
cavity, washed and resuspended in ice-cold 70% ethanol for FACS analysis (see above) or in lysis buffer for 
western blotting (see above).  
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Data presentation and analysis 
       All experiments were replicated at least three times. Data were expressed as means±SD. Western blots 
were quantified by densitometry and normalized vs β-actin. Reliability of results was also checked by 
randomizing samples during gel loading (not shown). Significance of the differences was evaluated by one-
way ANOVA;  p< 0.05, p< 0.01 and p< 0.001 were considered significant.  
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Figure Legends 
Fig.1  Effect of TAX on growth, morphology and survival of human HCC cells.  
(A) and (B) Flow-cytometric evaluation of apoptotic Huh7 and HepG2 cells after 6 and 24 hours of treatment 
with TAX at the concentrations indicated. Histograms report the percentage of hypodiploid (apoptotic) cells. 
Data are means±SD of 4 experiments. Significance of the differences vs controls: *** p<0.001. (C) and (D) 
Phase contrast pictures of cells untreated or treated with 0.1 M TAX for 6 and 24 hours. Bars 30 µm. 
Arrows indicate apoptotic-like figures. (E) and (F) Total number of cells treated with 0.1 M TAX for up to 
24 hours. Data are means±SD of 4 experiments. Significance of the differences vs controls: ***p< 0.001.  
 
Fig.2  Effects of TAX on DNA distribution in Huh7 and HepG2 hepatoma cells,  
(A) and (B) DNA distribution and apoptosis quantification. Cultures exposed to 0.1 M TAX for 6 or 24 
hours. Left panels: Huh7 cells; right panels: HepG2 cells. (A) Black arrows indicate the sub-G1 population, 
white arrows indicate G2/M-arrested cells. (B) respective fraction of apoptotic cells (hypodiploid DNA 
content). Data are means±SD of 4 experiments. Significance of the differences vs C: ***p< 0.001. 
 
Fig.3 TNF potentiates death induced by microtubular poisons and zVADfmk counteracts death by Tax-TNF.   
(A) Huh7 and HepG2 cells exposed for 24 hours to 0.1 M TAX , 0.2 g/mg/ml nocodazole (NOC) or 10 
M colchicine (COL), alone or combined with 15 ng/ml TNF. Histograms indicate the percentage of 
hypodiploid (apoptotic) cells. Data are means±SD of 4 experiments. Significance of the differences vs 
untreated controls: ***p< 0.001; vs TAX: °°p< 0.01 and °°°p< 0.001; vs nocodazole: 
###
p< 0.001; vs 
colchicine 
&&&
p< 0.001. (B) Cells exposed to 0.1 M TAX for 12, 18, 24 and 30 hours with TNF added for 
the last 6 hours into the cultures to a final concentration of 15 ng/ml, or to TNF for 30 hours with TAX added 
for the last 6 hours, and finally to TAX alone or TAX and TNF combined for 30 hours, as indicated. 
Histograms indicate the percentage of hypodiploid (apoptotic) cells. Data are means±SD of 4 experiments. 
Significance of the differences vs untreated controls: **p< 0.01 and ***p< 0.001; vs TAX: °p< 0.05, °°p< 
0.01 and °°°p< 0.001. (C) Effect of zVADfmk on apoptotic death in cells exposed to TAX or TAX+TNF for 
24 hours.  zVADfmk (20 μM final concentration) was added to the cultures 1 h before a 24 hour treatment 
with 0.1 M TAX and TAX plus 15 ng/ml TNF. Histograms represent percentages of hypodiploid cells 
(apoptotic). Significance of the differences vs C: ***p< 0.001; vs TAX: °°p< 0.01 and °°°p< 0.001; vs 
TAX+TNF: 
§§§
p< 0.001. 
 
Fig.4 Caspase 8, 9, and 3 activity in HCC cells treated with TAX or TAX+TNF.  
Huh7 (left panels) and HepG2 (right panels) cells exposed to 0.1 M TAX or TAX plus 15 ng/ml TNF for 2, 
6, 12 and 24 hours. Caspase activities measured as indicated in Materials and Methods, data (means±SD) 
expressed as nkatal×10
-5
/mg protein. Panels A and B, caspase 8; panels C and D, caspase 9; panels E and F, 
caspase 3. Significance of the differences vs controls: *p< 0.05, **p< 0.01 and ***p< 0.001; vs TAX: °p< 
0.05, °°p< 0.01 and °°°p< 0.001.  
19 
 
 
Fig.5 Effect of selective inhibitors on caspase 8 and 3 activities in HCC cells exposed to TAX or TAX+TNF 
for 24 hours.  
Caspase 8 (A) and 3 (B) activities in cells pretreated with AcDEVDcmk (20 µM) or zIETDfmk (20 µM) for 
1 hour, then exposed to 0.1 M TAX or TAX plus 15 ng/ml TNF for 24 hours. Data (means±SD) are 
expressed as nkatal×10
-5
/mg protein. Significance of the differences vs controls: **p< 0.01 and 
***p < 0.001; vs TAX: °p< 0.05, °°p< 0.01 and °°°p< 0.001; vs TAX+TNF: 
###
p< 0.001.  
 
Fig.6 Effects of TAX and TAX+TNF (24 hours) on total and membrane TNF-R1 expression in HCC cells. 
Panels A and B show representative western blots of TNF-R1 in Huh7 and HepG2 cells treated with 0.1 M 
TAX, 15 ng/ml TNF or TAX+TNF for 24 hours. Respective densitometric data are shown in panels C and D. 
Data (means±SD) are expressed as percentage of controls. Significance of the differences vs untreated 
controls: *p< 0.05 and ***p< 0.001. Fluorescence microscopy of Huh7 (E) and HepG2 (F) cells after DAPI 
staining and immunodecoration of TNF-R1 at the cell surface. Bars 20 µm. Cell surface TNF-R1 expression 
measured in Huh7 (G) and HepG2 (H) cells by flow cytometry.  
 
Fig.7 SOCS3 and STAT3 expression and effects of SOCS3 silencing in TAX- and TAX+TNF-treated HCC 
cells. 
(A) Representative western blots and (B) densitometric quantification of SOCS3, STAT3 and pSTAT3 levels 
in Huh7 and HepG2 cells after a 24 hour treatment with 0.1 M TAX or 15 ng/ml  TNF or TAX+TNF. Data 
are means±SD expressed as percentage of controls. Significance of the differences vs C: **p< 0.001 and 
***p< 0.001; vs TAX: °°°p< 0.001. (C) Representative western blot pattern of SOCS3 levels in HepG2 and 
Huh7 cells untreated or treated with siSOCS3 (100 pmol) for 24 and 48 hours. (D) Effect of SOCS3-siRNA 
or siC (100 pmol) on TNF-induced apoptosis: cells were transfected with siSOCS3 or nontargeting siRNA 
(siC) for 48 hours, then exposed to TNF (15 ng/ml) for further 24 hours. Histograms represent percentages of 
hypodiploid (apoptotic) cells in the culture. Data are means±SD of 4 experiments. Significance of the 
differences: vs untreated controls  **p< 0.001 and ***p< 0.001; vs TNF and siSOCS3: 
§§§
p<0.001. 
 
Fig.8 c-FLIP protein levels in HCC cells treated with TAX or TAX+TNF.  
Panels A and B show representative western blots of c-FLIP in Huh7 and HepG2 cells treated with 0.1 M 
TAX or 15 ng/ml TNF or TAX+TNF for 24 hours. Panels C and D show the respective densitometric data. 
Data (means±SD) are expressed as percentage of controls. Significance of the differences vs controls: 
***p< 0.001. 
 
Fig.9 TAX+TNF-induced cytotoxicity in a transplantable hepatoma.  
 (A) Sub-G1 fraction (% of total cell population) in AH-130 hepatoma cells obatined from mice treated with 
TAX (4 mg/kg body weight), TNF (10 μg/mouse), or both (for treatment schedule see Materials and 
methods). Data are means±SD of 4 animals/group. Significance of the differences vs untreated controls: 
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*p< 0.05, ***p< 0.001; vs TAX °°°p< 0.001. (B) Representative western blot of SOCS3 in AH-130 
hepatoma cells. (C) Respective densitometric data are means±SD expressed as percentage of untreated 
controls; significance of the differences vs controls: *p< 0.05, **p< 0.01; vs TAX °p< 0.05.  
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